great post @KingBuzzo get some thinking… so if Amgen do nothing lose patent life and becomes a generic. If P2 CPACS gets accelerated approval. Could Race no simply pair with generic off label and patent?
what is more likely, Amgen find some other combo that improves anti-cancer perhaps increasing side effects.
Pairs with Bisantrene so anti-cancer and cardio protect exclusivity and increases MTD.
When do we hear from Amgen next? My thinking is after P1 readouts. It’s also a foot in the door of Amgen want CPACS+Dox
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-55
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
